KR20160122849A - 면역자극성 플라스미드 - Google Patents

면역자극성 플라스미드 Download PDF

Info

Publication number
KR20160122849A
KR20160122849A KR1020167026797A KR20167026797A KR20160122849A KR 20160122849 A KR20160122849 A KR 20160122849A KR 1020167026797 A KR1020167026797 A KR 1020167026797A KR 20167026797 A KR20167026797 A KR 20167026797A KR 20160122849 A KR20160122849 A KR 20160122849A
Authority
KR
South Korea
Prior art keywords
sequence
nucleic acid
composition
group
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167026797A
Other languages
English (en)
Korean (ko)
Inventor
안드레아 아이커
헤르만 벨만
마르크 문네스
로미나 쇼어
앨버트 아브라함
크리슈티안 바이쓰
엘리자베트 펠드휘스
Original Assignee
바이엘 애니멀 헬스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이엘 애니멀 헬스 게엠베하 filed Critical 바이엘 애니멀 헬스 게엠베하
Publication of KR20160122849A publication Critical patent/KR20160122849A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A61K47/48046—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16771—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020167026797A 2014-02-28 2015-02-27 면역자극성 플라스미드 Withdrawn KR20160122849A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461946372P 2014-02-28 2014-02-28
US61/946,372 2014-02-28
PCT/EP2015/054131 WO2015128461A1 (en) 2014-02-28 2015-02-27 Immunostimulatory plasmids

Publications (1)

Publication Number Publication Date
KR20160122849A true KR20160122849A (ko) 2016-10-24

Family

ID=52598746

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167026797A Withdrawn KR20160122849A (ko) 2014-02-28 2015-02-27 면역자극성 플라스미드

Country Status (20)

Country Link
US (2) US10155950B2 (cg-RX-API-DMAC7.html)
EP (1) EP3110940A1 (cg-RX-API-DMAC7.html)
JP (1) JP6772065B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160122849A (cg-RX-API-DMAC7.html)
CN (1) CN106029867B (cg-RX-API-DMAC7.html)
AU (1) AU2015222102B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016019837A2 (cg-RX-API-DMAC7.html)
CA (1) CA2940794C (cg-RX-API-DMAC7.html)
CL (1) CL2016002146A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160393A (cg-RX-API-DMAC7.html)
DO (1) DOP2016000223A (cg-RX-API-DMAC7.html)
IL (1) IL247065A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016010993A (cg-RX-API-DMAC7.html)
PE (1) PE20170404A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016501705A1 (cg-RX-API-DMAC7.html)
RU (1) RU2740492C2 (cg-RX-API-DMAC7.html)
SV (1) SV2016005263A (cg-RX-API-DMAC7.html)
UA (1) UA118374C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015128461A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201605495B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016010993A (es) * 2014-02-28 2017-05-01 Bayer Animal Health Gmbh Plasmidos inmunoestimuladores.
WO2015187966A1 (en) 2014-06-04 2015-12-10 Aurasense Therapeutics, Llc Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
MX2017017141A (es) * 2015-06-26 2018-03-09 Bayer Animal Health Gmbh Metodos de modulacion de moleculas de vigilancia de adn citosolicas.
WO2017021266A1 (en) * 2015-07-31 2017-02-09 Bayer Animal Health Gmbh Enhanced immune response in porcine species
AU2016304343A1 (en) * 2015-07-31 2018-02-08 Bayer Animal Health Gmbh Enhanced immune response in aquatic species
EP3490598A1 (en) 2016-07-26 2019-06-05 Bayer Animal Health GmbH Increased fertility in bovine species
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CA3085661A1 (en) * 2017-12-15 2019-06-20 Bayer Animal Health Gmbh Immunostimulatory oligonucleotides
CN109646435B (zh) * 2019-01-11 2021-08-03 山东省农业科学院奶牛研究中心 厄他培南钠在制备防治牛传染性鼻气管炎药物中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5427791A (en) 1992-08-05 1995-06-27 Regents Of The University Of Minnesota Embryonal vaccine against Newcastle disease
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US5830878A (en) 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
DK1459766T3 (da) 1999-03-26 2008-10-13 Vical Inc Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
US20040002472A1 (en) 2000-01-21 2004-01-01 Audonnet Jean-Christophe Francis Vaccination or immunization using a prime-boost regimen
US6517218B2 (en) 2000-03-31 2003-02-11 Relume Corporation LED integrated heat sink
US7238356B2 (en) * 2001-04-24 2007-07-03 Innogenetics N.V. Core-glycosylated HCV envelope proteins
CA2452666A1 (en) 2001-07-02 2003-01-16 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
AU2002953015A0 (en) * 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
US20070134200A1 (en) 2003-03-26 2007-06-14 Wyeth Immunogenic composition and methods
AU2004280143A1 (en) 2003-10-11 2005-04-21 Tekmira Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
US20050181035A1 (en) 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
EP1786461A4 (en) * 2004-08-13 2010-03-03 Univ Pennsylvania ANTIBIOTICINESIS-FREE DNA VACCINES
UY29915A1 (es) 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
TWM297441U (en) 2006-03-30 2006-09-11 Cheng-Jiun Jian LED projection light source module
US7663229B2 (en) 2006-07-12 2010-02-16 Hong Kong Applied Science And Technology Research Institute Co., Ltd. Lighting device
CN101553498B (zh) * 2006-10-06 2012-08-08 斯克里普斯研究学院 用于引发对肿瘤相关巨噬细胞的免疫应答的dna组合物
WO2009046388A1 (en) * 2007-10-03 2009-04-09 United States Medical Research & Material Command Cr-2 binding peptide p28 as molecular adjuvant for dna vaccines
CA2719614C (en) 2008-03-25 2018-05-01 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)
CN102202685A (zh) 2008-10-31 2011-09-28 贝林格尔.英格海姆维特梅迪卡有限公司 包含来自牛枝原体的抗原的多种抗原在多价疫苗组合物中的用途
US20120064151A1 (en) * 2009-05-14 2012-03-15 Bayer Animal Health Gmbh Enhanced immune response in avian species
JP6058550B2 (ja) 2010-12-22 2017-01-11 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ ウシの種における免疫応答の増強
CL2011000065A1 (es) 2011-01-11 2011-04-15 Univ Concepcion Formulacion veterinaria para la prevencion y eliminacion de infeccion por cepas de e. coli stec, que comprende un plasmido recombinante que codifica un factor de virulencia y liposoma cationico como vehiculo, uso de dicha formulacion para tratar preferentemente bovinos y porcinos.
MX2016010993A (es) * 2014-02-28 2017-05-01 Bayer Animal Health Gmbh Plasmidos inmunoestimuladores.

Also Published As

Publication number Publication date
CN106029867B (zh) 2020-02-14
AU2015222102A1 (en) 2016-08-18
RU2740492C2 (ru) 2021-01-14
CA2940794A1 (en) 2015-09-03
EP3110940A1 (en) 2017-01-04
SV2016005263A (es) 2018-01-16
UA118374C2 (uk) 2019-01-10
CR20160393A (es) 2017-12-14
DOP2016000223A (es) 2016-09-30
RU2016138321A (ru) 2018-03-30
PH12016501705A1 (en) 2016-10-03
CA2940794C (en) 2022-05-31
US20180312842A1 (en) 2018-11-01
US10155950B2 (en) 2018-12-18
JP6772065B2 (ja) 2020-10-21
JP2017512202A (ja) 2017-05-18
IL247065A0 (en) 2016-09-29
WO2015128461A1 (en) 2015-09-03
MX2016010993A (es) 2017-05-01
BR112016019837A2 (pt) 2017-10-17
RU2016138321A3 (cg-RX-API-DMAC7.html) 2018-11-12
ZA201605495B (en) 2022-08-31
CL2016002146A1 (es) 2017-08-04
US20150267201A1 (en) 2015-09-24
PE20170404A1 (es) 2017-05-14
AU2015222102B2 (en) 2021-08-19
CN106029867A (zh) 2016-10-12
US10851379B2 (en) 2020-12-01

Similar Documents

Publication Publication Date Title
RU2740492C2 (ru) Иммуностимулирующие плазмиды
US12305173B2 (en) Immunostimulatory compositions
KR20220006527A (ko) 리소좀 장애에 대한 유전자 요법
KR20120016661A (ko) 항생제-미함유 플라스미드
KR20180021874A (ko) 시토졸 dna 감시 분자의 조절 방법
AU2016302436B2 (en) Enhanced immune response in porcine species
CN108712912B (zh) 在水生物种中增强的免疫应答
KR102473370B1 (ko) 소 종에서의 수정능 상승
HK1229849B (zh) 免疫刺激性质粒
HK1229849A1 (en) Immunostimulatory plasmids
RU2799523C1 (ru) Иммуностимулирующие композиции
HK1256183A1 (en) Enhanced immune response in aquatic species
HK40007864A (en) Increased fertility in bovine species

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160927

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination